The EGF Receptor (EGFR) and its downstream signaling are implicated in lung cancer development. Therefore, much effort was spent in developing specific tyrosine kinase inhibitors (TKIs) that bind to the EGFR ATP-pocket, blocking EGFR phosphorylation/signaling. Clinical use of TKIs is effective in a subset of lung cancers with mutations in the EGFR kinase domain, rendering the receptor highly susceptible to TKIs. However, these benefits are limited, and emergence of additional EGFR mutations usually results in TKI resistance and disease progression.
Introduction
Smoking-related lung cancer is the leading cause of cancer deaths in both men and women in the United States. However, the molecular mechanisms underlying the induction of lung cancer by cigarette smoke (CS) are still poorly understood.
It is currently known that over-expression and deregulation of receptor tyrosine kinases (RTKs) are tightly connected to tumorigenesis. Of importance is the epidermal growth factor receptor (EGFR), a member of the ErbB family of RTKs, which also includes ErbB2, ErbB3, and ErbB4 (1) . EGFR is implicated in a number of cancers including lung cancer (2) (3) (4) . This receptor plays a role in normal cell processes, but the deregulation of its activation and downstream signaling leads to aberrant cell proliferation and cancer development (5-7).
The activation mechanism of EGFR in lung cancer has been a subject of intense studies, and a classical model of EGFR activation has been established wherein ligand binding induces receptor dimerization.
This leads to activation of the EGFR intracellular tyrosine kinase domain and subsequent autophosphorylation of specific tyrosines on the C-terminal "tail" of the receptor, initiating a cascade of downstream signaling.
Over the last decade specific tyrosine kinase inhibitors (TKIs) have been developed to block EGFR activation / signaling. TKIs are small molecules that inhibit TK activity via binding reversibly to the EGFR ATP binding site; several TKIs are approved by the US Food and Drug Administration (FDA) for the treatment of metastatic lung cancer, including Erlotinib (Tarceva), while other TKIs are in preclinical trials (e.g. TKI AG1478) (8) (9) (10) (11) . Trials with TKIs indicated that tumor responses to the drugs were remarkable and sustainable in specific subsets of non-small cell lung cancer (NSCLC) patients that possess activating EGFR mutations (12) (13) (14) . Intriguingly however, it has been noted anecdotally that patients responsive to TKI therapy developed TKI resistance if they began smoking (15) . In the current study, we investigated whether smoking-related TKI resistance may be explained mechanistically by alterations in the EGFR conformation and signaling. Recently, we showed that EGFR activation induced by CS was in fact independent of ligand binding (5) . Specifically, one of the major reactive oxidants in the gas phase of CS, hydrogen peroxide (H 2 O 2 ), caused aberrant phosphorylation and activation of the EGFR (5) in human airway epithelial (HAE) cells. The abnormal phosphorylation of the receptor in cells exposed to H 2 O 2 -induced oxidative stress also acquired an aberrant activated conformation that impaired canonical dimerization of EGFR (17) . This activated EGFR was neither ubiquitinated nor subsequently degraded due to its inability to bind the E3-lygase, c-Cbl. This allowed EGFR to remain active for a longer period at the plasma membrane, thereby causing prolonged survival signals that contributed to uncontrolled cell growth (5) (6) 18 ).
Here we present evidence for a novel, active EGFR conformation caused by oxidative stress (ox-stress) from CS exposure. Unlike the canonical EGF-induced conformation, it does not dimerize, and it interacts strongly with c-Src, resulting in ligand-independent EGFR activation that is resistant to inhibition by TKIs.
In fact, both wild type (WT) and TKI-sensitive EGFR mutants (MTs) develop TKI resistance through this mechanism after CS exposure. These findings help to elucidate how cigarette smoke induces aberrant EGFR signaling which promotes lung cancer and therapy resistance. Hamid Band, University of Nebraska Medical Center) (19) have been employed in this study. All the cell lines used in this study were previously characterized by others, as reported (19) (20) (21) ; no authentication was done by the authors. Details regarding the various media and source of reagents are provided in the online supplement.
Cigarette smoke exposure. Serum-starved cells were exposed to cigarette smoke as described before (5) . Details regarding the exposure chamber are in the online supplement.
Immuno-precipitation (IP).
200-400 µg of total protein extracts were incubated for 3 h with 2-4 µg of antibodies (Abs): anti (α) 528 (against EGFR) or α4-2 (αactive-EGFR, kindly provided by Dr. K. Omi, Fujirebio Inc., Tokyo, Japan (22) ). 50 µl of 50% protein A-agarose bead complexes (Repligen) were added to the samples and incubated for 90 min. Four washes (by sequential centrifugation and resuspension) with the NP-40-lysis buffer were done prior to re-suspending the IPs in the loading dye for SDS-PAGE, as described before (5, 17) . Anchorage independent growth assay (soft agar/agarose assay). 5000 Single-suspended NIH-3T3 cells over-expressing the L858R EGFR MT were mixed in culture medium (38°C) containing 0.275% low melting point Agarose (Fermentas) and then seeded in "6-well plate" dishes (Falcon) on top of 0.6% Agar (BTS) layer, as previously described by others (19) . Growing colonies (composed of at least 3 cells) were randomly counted by optical microscopy at 100x magnification.
Statistical analysis. Each treatment and experiment (IB, IP/IB or soft agar/agarose assay) was repeated at least three times. The plotted data are reported as mean ± Standard deviations (St-Devs). Statistical significance was determined by Student's t-test and p-value < 0.05 was considered statistically significant.
Results

CS-induced phosphorylation of EGFR is not inhibited by TKIs, AG1478, Erlotinib and Gefitinib.
Small-molecule tyrosine kinase inhibitors (TKIs), i.e. AG1478, Erlotinib and Gefitinib are used to target the EGFR, suppressing its kinase activity by reversibly blocking the ATP-binding site of the receptor.
Thus, we tested the efficacy of these TKIs on CS-induced phosphorylation of EGFR.
Serum-starved A549 cells were incubated (or not) with 1 µM AG1478 or Erlotinib or Gefitinib for 30 minutes and then treated (or not) with 100 ng/ml EGF or smoke from 1 cigarette for an additional 30 minutes. Cells were lysed, EGFR was immuno-precipitated (IPed) and immuno-blotted (IBed) for total receptor, total tyrosine (Tyr) phosphorylation, and specific Tyr (Y) phosphorylation sites, as indicated in Cigarette smoke exposure leads to downstream survival and proliferation signaling that is not inhibited by TKIs. Extracellular signal-regulated kinases (ERK) 1/2 and Akt (also known as protein kinase B) are two well known mediators of cell proliferation and survival, and are known to be involved in cell transformation when persistently activated (23) (24) . We have shown previously (5) that exposure to smoke from one cigarette for 45 min activates downstream ERK 1/2 and Akt signaling. Furthermore, both EGFR and ERK1/2 phosphorylation persisted for up to two hours after the removal of the treatment medium exposed to CS, whereas removal of EGF returns phosphorylation to near baseline levels at these time points. This further demonstrated that these signals may be prolonged due to the inability of the EGFR to be degraded under CS-induced ox-stress.
Importantly, here we demonstrate, in the supplementary (Sup. (Fig. 2 ). Since it has been shown that conformational changes in the intracellular domain of EGFR may lead to direct interaction between EGFR and c-Src (7, 19) , such an observed interaction under CS exposure provides an indication for a novel conformation of the EGFR. This interaction also explains the strong level of phosphorylation observed at Y845 (Fig. 1) .
Activated EGFR does not dimerize under CS. We have shown before that H 2 O 2 -generated ox-stress did not induce formation of EGFR dimers in the presence of the cross linker EDAC both in airway epithelial cells and in NIH-3T3 cells over-expressing EGFR (17) . Here we investigated the mechanism of EGFR dimerization under CS. Serum-starved A549 cells were initially exposed (or not) for 15 min. to 100 ng/ml EGF or to smoke from half a cigarette. Then, a cross-linking agent, EDAC (1 mM), was added (or not) for additional 15 min. (in the presence of EGF or CS, respectively). Cells were lysed and an equal amount of proteins (50 µg) were separated by SDS-PAGE and IBed for total and Tyr-phosphorylated EGFR (Fig. 3) . As expected, treating with EGF and the cross linking agent resulted in the formation of a dimer with a band at ~340-360 kDa. On the other hand, CS induced the activation of EGFR, but no dimer was detected in the presence of EDAC (Fig. 3) . This demonstrates that CS-induced activation of EGFR does not result in the "classical" dimerization of EGFR.
CS induces a novel active conformation of the EGFR intracellular domain.
In order to substantiate our hypothesis that the EGFR acquires a new active conformation under CS exposure, we employed a novel "conformational change-sensitive" EGFR monoclonal antibody (mAb), anti-(α) 4-2 Ab (22). This antibody recognizes epitopes (amino acids 956-998) of EGFR in non-denaturing conditions. These epitopes are in the intracellular domain of EGFR and were found to be exposed only in the canonically ligand-activated WT EGFR. Additionally, the 4-2 mAb binds constitutively to the L858R EGFR MT since the same epitopes are constitutively exposed in that MT (22) .
Serum-starved A549 cells were treated (or not) with EGF or CS as before. EGFR was IPed from 300 µg of total cell lysate using 3 µg of either α4-2 mAb or α528 mAb and then IBed for total EGFR (α2232) (Fig. 4A, B) . The α528 mAb pulled down EGFR with the same affinity for all of the treatments, as expected (Fig. 4A) . The α4-2 mAb bound significantly higher to the EGF-treated EGFR than to the untreated receptor. However, under CS exposure, although EGFR is activated (Fig. 1) as verified by strong blotting of its auto-phosphorylation sites (using αp-Y1173 Ab), its affinity to that special Ab, which marks a canonical activated conformation, did not change (Fig. 4A) . The α4-2 mAb binds EGFR under EGF stimulation with an affinity ~700% greater than control conditions, but this does not happen under CS activation (Fig. 4B) , indicating that the intracellular active conformation of EGFR under CS does not resemble that of the EGF-activated receptor.
Furthermore, we investigated the ability of the α4-2 mAb to bind the L858R EGFR MT. This was done by employing NIH-3T3 cells stably over-expressing this MT. Cells were treated with EGF or CS, as before, and EGFR was IPed from total cell lysates with either α4-2 or α528 mAbs, and IBed for total EGFR (α2232). Figures 4C and 4D confirm that the α4-2 mAb binds to the L858R EGFR MT with high affinity (Fig. 4C) , as previously reported (22) . However, its affinity is reduced upon CS exposure, even though the phosphorylation of the MT EGFR under EGF and CS exposure is comparable (data not shown). Indeed, there is ~40% reduction in the amount of MT EGFR pulled down by α4-2 mAb after CS exposure (Fig. 4C ). This suggests that CS changes the conformation of both WT and MT L858R EGFR at the level of the intracellular domain, most likely at the level of the kinase domain. Therefore, this novel active conformation could be no longer inhibited by the TKIs, as described above.
The TKI-sensitive L858R somatic mutant EGFR acquires resistance to TKIs under CS. Since we observed that the TKIs were ineffective in inhibiting EGFR activation under CS, we tested their efficacy against the L858R EGFR MT upon CS exposure.
NIH-3T3 cells stably over-expressing the L858R EGFR MT were serum-starved and incubated (or not) with 1 µM AG1478 or Erlotinib for 30 minutes and then treated (or not) with 100 ng/ml EGF or smoke from 1 cigarette for an additional 30 minutes. Cells were lysed, EGFR was IPed and IBed for total receptor, total tyrosine phosphorylation, and specific tyrosine phosphorylation sites, as above. 
As shown in figure 5 , the L858R EGFR MT is constitutively active (as expected (7, 13, 25) ), while its phosphorylation is slightly increased under both EGF and CS. The constitutive activation of the EGFR MT as well as the EGF-induced activation were inhibited by both TKIs, AG1478 (Fig. 5A) and Erlotinib (Fig. 5B) , at the auto-phosphorylation sites Y1068 and Y1173 compared to untreated cells. However, this TKI-sensitive EGFR MT becomes resistant to TKI treatments upon exposure to CS (Fig. 5A relative to   AG1478 and Fig. 5B relative to Erlotinib). Both the auto-phosphorylation sites Y1068 and Y1173 and the trans-phosphorylation site Y845 remained active under CS exposure even with the pre-incubation of AG1478 or Erlotinib. To further validate this response, another drug-sensitizing mutant EGFR with an inframe deletion in exon 19 (EGFR ∆746-750) (which encodes part of the kinase domain) was subject to the same TKI treatments. As with the L858R EGFR MT, this deletion mutant acquired resistance to both
AG1478 and Erlotinib under CS (data not shown).
Finally, we also repeated the CS/TKI treatments in the NSCLC cells, HCC827, which are harboring the TKI-sensitive EGFR mutant: ∆746-750 MT (26) . Sup. figure 2 shows that exposure to CS of these TKIsensitive NSCLC cells also causes EGFR resistance to TKIs.
Overall, our data suggest that CS induces a novel active conformation of EGFR which differs from the EGF-induced one and also is different from that of the L858R EGFR MT and other TKI-sensitive mutants. Such a novel acquired conformation could be the reason for the receptor's acquired resistance to EGFR-transformed cells in the presence or absence of TKI. We employed the NIH-3T3 cells stably overexpressing L858R EGFR, which were previously demonstrated to be very suitable for testing such transforming potential in soft agar/agarose colony assay (19) .
Single-suspended cells were seeded inside a layer of 0.275% Agarose (in culture medium), and on top of a 0.6% Agar gel layer, as described in Material and Methods. Subsequently, the cells were fed daily with medium that was exposed, or not, to smoke from 1 cigarette for 30' in the presence or absence of 1 µM gefitinib. Sup. figure 3 shows that incubation with 1 µM gefitinib could effectively inhibit the colony formation of the EGFR-transformed cells (in comparison to control-untreated (NT) cells). However, gefitinib treatment became ineffective upon CS exposure of those cells. This confirmed that CS exposure can overcome the TKI-sensitivity of EGFR-transformed cells, thus sustaining clonal growth of lung cancer even in the presence of TKI drugs.
Discussion
We define here the initial post-translational changes that occur in EGFR with cigarette smoke (CS) exposure of airway epithelial cells. These alterations in EGFR lead to aberrant signaling and cell proliferation, and ultimately constitute a molecular basis for CS-induced lung cancer initiation and promotion (5).
Given its frequent deregulation in non-small-cell lung cancer (NSCLC), EGFR became a logical target for therapy. The first targeted strategies employed a monoclonal antibody antagonist to the ligand binding domain (cetuximab) (27) . However, more dramatic responses were observed with small molecule reversible inhibitors of the tyrosine kinase domain (TKIs, gefitinib or erlotinib). Though highly gratifying, these remarkable clinical responses were restricted to a subset of cases, typically adenocarcinoma occurring in female never-smokers of Japanese origin (27) . Subsequently, these responders were found to possess mutations in the EGFR TK domain, which were thought to confer a selective growth advantage that could be neutralized by the TKIs (13, 25, (28) (29) (30) "classic", among these somatic mutations are the exon 19 deletion mutation (∆746-750) and the exon 21 single-point substitution mutation (L858R) (31) (32) .
However, it has been recently observed that the same EGFR mutations are not limited to adenocarcinoma from female never-smokers. Indeed, a large number (43%) of EGFR mutations are actually found in adenocarcinoma tumor specimens from men and people who are smokers or former smokers (33) . Yet, these smoking patient groups (harboring EGFR mutations, which are sensitive to TKIs) do not appear to benefit from the TKI treatment. This suggests that smoking could affect the TKI sensitivity of EGFR activating mutations.
Interestingly, it was recently shown that these somatic adenocarcinoma mutations induce aberrant downstream signaling that resembles that of the wild-type (WT) EGFR exposed to CS (5). Studies carried out by Dr. Yarden's group (6) showed that the EGFR mutant L858R presented an impaired association with c-Cbl and ubiquitination as had been previously reported by our group for the WT EGFR exposed to CS-induced ox-stress (5, 34) . Moreover, a recent publication by Dr. Band's group (7) demonstrated that the mutant EGFR, but not the WT receptor, undergoes perinuclear accumulation and co-localization with recycling endosomal markers such as Rab 11, suggesting that mutant EGFRs display a different pattern of endocytosis, again similar to what had been previously described by our group for the WT EGFR exposed to CS (5, 18) . Notably, the aberrant EGFR internalization has been proposed as one of the mechanisms that can generate TKI resistance with no additional somatic mutations (35) (36) . This may be further complemented by our previous finding (5) that under CS exposure EGFR is also capable of trafficking aberrantly to the perinuclear region.
Importantly, while the "classic" somatic mutations and CS exposure may result in similar downstream signaling phenotypes, in all likelihood they nonetheless represent distinct EGFR conformations and structure (16, 37 
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This is most notably evidenced by the clinical findings that the sensitivity to TKIs is mostly observed in adenocarcinoma of non-smokers, whereas CS exposure is mostly associated with squamous cell carcinoma and adenocarcinoma that are not sensitive to TKIs. Perhaps for this reason, non-smoking adenocarcinoma patients who initially respond to TKIs develop resistance when they begin to smoke, while smoking patients (whose cancer developed in the setting of CS exposure) are resistant to TKI in the first place.
Therefore, here we propose that the aberrant mechanism of EGFR ligand-independent (5) activation in HAE cells exposed to CS is due to a novel and uncharacterized conformation of the intracellular domain of the receptor that leads to an active, yet stabilized, EGFR that is also resistant to TKI drugs. Therefore, CS-induced EGFR changes may contribute to both the initial disease pathogenesis in smokers and to emergence of TKI-resistance in nonsmokers who at first are sensitive to TKI.
To provide direct evidence for the conformational change of EGFR under CS, we used a novel "conformational change-sensitive" EGFR antibody (α4-2 mAb) (22), which we used before (17) . This antibody was shown to bind epitopes of EGFR that are exposed only subsequent to EGFR canonical activation by its ligand, EGF, which induces a conformational change of the kinase domain (16) . This antibody also binds constitutively to the L858R EGFR MT because the same epitopes are constitutively exposed in this mutant due to its open activating loop of the kinase domain (16, 22) .
Interestingly, even though EGFR is highly activated by CS, the α4-2 mAb binds to the CS-stimulated EGFR with a much lower affinity than to that activated by EGF (Fig. 4A and B) . Furthermore, we demonstrated that the high affinity of the α4-2 mAb for the L858R EGFR MT also dropped ~40% upon CS exposure. This was not the case upon EGF stimulation (Fig. 4C and D) , indicating that CS exposure induces an active state of the EGFR that differs from that of the "conventional"/ EGF-stimulated EGFR. Another indication for a unique conformational change of EGFR under CS-induced ox-stress was supported by the finding that EGFR was strongly associated with c-Src only upon CS (and not EGF) exposure of HAE cells (Fig. 2) . We reported previously that highly phosphorylated Cav-1 is strongly bound to EGFR under CS-induced ox-stress (5, 18) . Others reported that c-Src stably interacts with ErbB2, but not with WT EGFR, because of the difference in their kinase domains (38) . This c-Src binding was shown to confer elevated transformation ability (39) . Furthermore, the L858R EGFR MT could also bind c-Src (19) .
Collectively, these findings suggest that CS exposure may induce TKI resistance solely through posttranslational molecular changes without additional somatic mutations. These molecular alterations consist of an EGFR aberrant phosphorylation pattern caused by CS exposure (5) accompanied by an aberrant conformational change. A possible hypothesis is that this conformational change limits TKI accessibility to the ATP binding site of the receptor, thereby preventing the inhibitory effect of the drug and allowing continuous EGFR signaling and cell proliferation (see model in Fig. 6 ). Accordingly, we also provide evidence that CS exposure can abolish the TKI-dependent inhibition of ERK 1/2 and Akt activation (Sup. Fig. 1 ) and of the anchorage independent growth of EGFR-transformed cells in soft agar/agarose assay (Sup. Fig. 3 ).
Of note is that even an irreversible EGFR inhibitor, such as CL387785, turned to be only 50% efficient in inhibiting EGFR activation (phosphorylation) if the cells were simultaneously exposed to the inhibitor and to CS (data not shown). Importantly, we have also carried out control experiments addressing whether the TK inhibitors may be "damaged" under CS exposure. We found that it was not the case. The effectiveness of the CS-exposed TKIs was evaluated in EGF-stimulated cells and was shown to be as potent as before the TKIs were exposed to CS (data not shown).
Taken together, we show herein that EGF-stimulated WT EGFR, L858R and ∆746-750 EGFR MTs of the TKIs AG1478, Erlotinib or Gefitinib (Fig. 1, 5 and Sup. with 100 ng/ml EGF for 15 min. or exposed to smoke from 1 cigarette for 30 min. EGFR was IPed from 300 μg of the total cell lysates using either α528 or α4-2 Ab and then IBed for total receptor or for Tyr- 
